Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

How Is CJC-1295 No DAC Administered in Research? (Protocols)

How Is CJC-1295 No DAC Administered in Research? (Protocols) CJC-1295 No DAC (also called Modified GRF 1-29) is administered via subcutaneous injection in research settings. But the dosing frequency is radically different from what non-specialists expect. With

By Recovery & Performance Peptides Editorial Team

How Is CJC-1295 No DAC Administered in Research? (Protocols)

CJC-1295 No DAC (also called Modified GRF 1-29) is administered via subcutaneous injection in research settings. But the dosing frequency is radically different from what non-specialists expect. Without the DAC (Drug Affinity Complex) modification, this growth hormone-releasing hormone (GHRH) analog has a half-life of approximately 30 minutes, meaning it must be dosed multiple times per day to maintain therapeutic plasma levels. Research protocols typically specify 100–200 mcg per injection, administered 1–3 times daily, timed to coincide with natural growth hormone pulse patterns.

Our experience working with researchers across hundreds of peptide studies reveals a consistent pattern: the administration protocol determines whether CJC-1295 No DAC produces meaningful physiological effects or simply generates transient plasma spikes that dissipate before downstream signaling cascades activate. The gap between effective and ineffective administration comes down to three things most general peptide guides never mention. Injection timing relative to meals, reconstitution stability windows, and the interaction between dosing frequency and endogenous GH pulse architecture.

How is CJC-1295 No DAC typically administered in research protocols?

CJC-1295 No DAC is administered via subcutaneous injection at doses of 100–200 mcg, delivered 1–3 times daily in research settings. The compound is reconstituted with bacteriostatic water before use, stored at 2–8°C, and injected into abdominal or thigh tissue. Unlike CJC-1295 with DAC (which allows weekly dosing), the No DAC variant requires multiple daily injections because its plasma half-life is approximately 30 minutes. Making continuous exposure impossible without frequent administration.

The standard definition of CJC-1295 No DAC administration stops at 'subcutaneous injection'. But that misses the mechanistic reason why injection frequency and timing matter so profoundly. GHRH analogs like CJC-1295 No DAC stimulate pulsatile growth hormone release from the anterior pituitary, meaning their efficacy depends on synchronizing exogenous peptide delivery with the body's endogenous GH pulse windows (which occur roughly every 3–5 hours). Administering the compound randomly throughout the day generates weaker IGF-1 responses than dosing it strategically before natural pulse periods. This article covers the exact reconstitution protocol research-grade CJC-1295 No DAC requires, the dosing schedules that align with physiological GH architecture, and the storage mistakes that cause peptide degradation before the first injection even occurs.

Research Injection Protocols: Dosing Frequency and Timing

CJC-1295 No DAC is administered in research at 100–200 mcg per injection, with most protocols specifying 1–3 doses daily depending on study objectives. Single daily dosing (typically pre-sleep) mimics the natural nocturnal GH surge, while twice-daily protocols (morning and pre-sleep) target both waking and nocturnal pulse windows. Three-times-daily administration (morning, post-workout, pre-sleep) is reserved for studies examining maximal GH stimulation or anabolic signaling pathways.

The dosing frequency directly impacts IGF-1 elevation magnitude and duration. Research published in The Journal of Clinical Endocrinology & Metabolism demonstrated that pulsatile GHRH administration produces higher peak GH levels than continuous infusion, even when total peptide exposure is equivalent. The pituitary response is frequency-dependent, not dose-dependent beyond a threshold. CJC-1295 No DAC's 30-minute half-life makes it inherently pulsatile: plasma concentrations spike within 15–20 minutes post-injection and return to baseline within 90–120 minutes.

Injection timing relative to meals is protocol-critical. Elevated blood glucose and free fatty acids blunt GH secretion through somatostatin release, meaning CJC-1295 No DAC administered within 2 hours of a carbohydrate-heavy meal produces 40–60% lower GH output than fasted-state administration. Standard research protocols specify administration on an empty stomach (minimum 3 hours post-meal) or immediately upon waking. Post-workout timing is mechanistically sound. Resistance exercise transiently suppresses somatostatin, creating a permissive window for GHRH-stimulated GH release.

Reconstitution and Storage: Preparing Research-Grade CJC-1295 No DAC

CJC-1295 No DAC arrives as lyophilized powder and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) before injection. Standard reconstitution ratios range from 1mg peptide per 1mL water to 1mg per 2mL, depending on desired injection volume per dose. The reconstitution process itself is straightforward. Inject bacteriostatic water slowly down the vial wall (never directly onto the peptide cake), then gently swirl until dissolved. But the post-reconstitution stability window is where most protocols fail.

Once reconstituted, CJC-1295 No DAC must be refrigerated at 2–8°C and used within 28 days. Peptides are temperature-sensitive. Any excursion above 8°C accelerates degradation through oxidation and hydrolysis of the amino acid chain. Unlike larger proteins with tertiary structure that denature visibly, small peptides like CJC-1295 degrade without any change in appearance. A vial left at room temperature for 6 hours looks identical to a properly stored vial but may have lost 30–50% potency.

Unreconstituted lyophilized CJC-1295 No DAC should be stored at −20°C for long-term stability (up to 24 months). Freeze-thaw cycles degrade peptides irreversibly, so researchers divide bulk powder into single-use aliquots before freezing. Our research peptide collection includes detailed reconstitution guides with every shipment. Because peptide efficacy in research is only as reliable as the preparation protocol.

Subcutaneous Injection Technique: Site Selection and Administration

Subcutaneous injection delivers CJC-1295 No DAC into the fatty tissue layer beneath the skin, where it diffuses into systemic circulation over 10–20 minutes. Standard injection sites include abdominal tissue (2 inches lateral to the navel), anterior thigh, or upper outer arm. Abdominal injections are preferred in research protocols because adipose tissue depth is more consistent across subjects, reducing inter-individual pharmacokinetic variability.

Injection technique follows standard aseptic protocol: (1) swab injection site with 70% isopropyl alcohol, (2) pinch skin to create a subcutaneous fold, (3) insert needle at 45–90° angle (angle depends on needle length and tissue depth), (4) inject slowly over 5–10 seconds, (5) withdraw needle and apply gentle pressure. Insulin syringes (29–31 gauge, 0.5mL capacity) are standard. Smaller gauge reduces tissue trauma and injection site reactions.

Rotating injection sites across multiple locations (left abdomen, right abdomen, left thigh, right thigh) prevents lipohypertrophy (localized fat accumulation) and maintains consistent absorption kinetics. Some research protocols specify contra-lateral rotation (alternating left/right sides daily), while others use a four-site rotation pattern over consecutive injections. The pharmacokinetic impact of site rotation is minimal for CJC-1295 No DAC. Absorption half-time varies by fewer than 5 minutes between abdominal and thigh sites.

CJC-1295 No DAC vs With DAC: Administration Comparison

Half-Life

~30 minutes

6–8 days

The DAC modification extends circulation time by binding to serum albumin, but some researchers prefer the No DAC version for controllable, pulsatile GH release

Dosing Frequency

1–3 times daily

Once weekly

No DAC requires daily commitment but allows precise timing around meals, sleep, and training

Typical Dose

100–200 mcg per injection

1–2 mg per week

Per-injection doses are lower for No DAC, but cumulative weekly exposure is similar between variants

GH Release Pattern

Pulsatile (mimics natural secretion)

Sustained elevation (non-physiological)

Pulsatile patterns align with endogenous GH architecture; sustained elevation may downregulate pituitary responsiveness over time

Research Applications

Acute GH response studies, anabolic signaling, pulse-timing investigations

Long-term IGF-1 elevation studies, convenience-focused protocols

No DAC is preferred when timing precision and natural pulsatility matter; With DAC is chosen for extended exposure without frequent dosing

The with-DAC variant isn't superior. It's a different tool. Researchers studying circadian GH patterns or post-exercise anabolic windows choose the No DAC version specifically because it allows timed interventions. The DAC-modified version creates steady-state plasma levels that don't reflect physiological GH secretion architecture.

Key Takeaways

CJC-1295 No DAC is administered via subcutaneous injection at 100–200 mcg per dose, typically 1–3 times daily in research protocols.

The compound has a plasma half-life of approximately 30 minutes, requiring multiple daily doses to maintain therapeutic exposure. Unlike the DAC variant, which allows weekly administration.

Reconstituted CJC-1295 No DAC must be stored at 2–8°C and used within 28 days; unreconstituted powder should be kept at −20°C for long-term stability.

Injection timing relative to meals is protocol-critical. Fasted-state administration produces 40–60% higher GH output than post-meal dosing due to reduced somatostatin interference.

Abdominal subcutaneous tissue is the preferred injection site in research settings because adipose depth variability is lower than other sites, reducing pharmacokinetic inconsistency across subjects.

Pulsatile dosing (matching natural GH pulse windows) generates higher peak GH levels than continuous exposure, even at equivalent cumulative doses. Frequency matters more than total quantity.

What If: CJC-1295 No DAC Research Scenarios

What If the Reconstituted Peptide Was Left at Room Temperature Overnight?

Discard it immediately and prepare a fresh vial. Peptides degrade rapidly above 8°C. A single 8-hour room-temperature exposure can reduce potency by 30–50% through oxidative breakdown of methionine residues and hydrolysis of peptide bonds. The degradation is irreversible and invisible. The solution will look identical, but the biological activity is permanently compromised. Research data integrity depends on discarding compromised samples rather than hoping residual activity is sufficient.

What If Injection Site Reactions (Redness, Swelling) Develop?

Rotate to a different anatomical site and assess whether the reaction was localized to one area or systemic. Mild injection site reactions (erythema, minor swelling lasting fewer than 24 hours) occur in 10–15% of subcutaneous peptide administrations and typically resolve without intervention. Persistent reactions suggest contamination (improper reconstitution technique), allergic response to bacteriostatic water preservatives, or injection technique issues (injecting too quickly, reusing needles). If reactions occur at multiple sites across different vials, consider switching to sterile water for reconstitution or consulting with institutional biosafety protocols.

What If Research Objectives Require Dosing More Than Three Times Daily?

Consider switching to CJC-1295 with DAC or continuous subcutaneous infusion via micro-pump. Dosing CJC-1295 No DAC more than three times daily offers diminishing returns. The pituitary GH secretory capacity has refractory periods between pulses, meaning excessive stimulation doesn't proportionally increase output. Research examining sustained GH elevation (rather than pulsatile patterns) is better served by DAC-modified peptides or continuous GHRH infusion protocols, which maintain stable plasma concentrations without requiring hourly injections.

The Unflinching Truth About CJC-1295 No DAC Administration

Here's the honest answer: most peptide administration failures in research aren't injection technique errors. They're storage and reconstitution mistakes that happen before the needle ever touches skin. A vial stored at 10°C instead of 4°C loses measurable potency every week. A researcher who reconstitutes a 5mg vial with 5mL bacteriostatic water but only uses 1mL over 28 days has wasted 80% of the peptide to degradation. The compound sitting in that syringe after week three? It's expensive saline with trace amino acids.

The second truth: dosing frequency matters more than dosing quantity for CJC-1295 No DAC. A researcher administering 300 mcg once daily will see lower IGF-1 responses than one administering 100 mcg three times daily at physiologically timed intervals. The pituitary doesn't respond linearly to GHRH analogs. It responds to pulsatile stimulation patterns. Flooding the system with a single large dose once daily misses the entire mechanistic advantage of using a short-half-life peptide.

CJC-1295 No DAC works when administered with precision. That precision includes temperature control, reconstitution sterility, injection timing, and site rotation. Skip any one element and research outcomes become unreliable.

Our dedication to quality extends across our entire product line. You can explore the potential of other research compounds like our FAT Loss Stack and see how our commitment to purity and exact amino-acid sequencing extends across our full peptide collection. Every batch undergoes rigorous third-party testing to verify what's on the label matches what's in the vial. Because research-grade means something.

The reality is that CJC-1295 No DAC administration in research isn't complicated. But it's unforgiving. Temperature excursions, reconstitution shortcuts, and mistimed injections don't produce partial results. They produce no results. The protocols exist for a reason: peptides are fragile, expensive, and only biologically active when handled correctly from synthesis to injection.

Frequently Asked Questions

CJC-1295 No DAC is typically injected 1–3 times daily in research settings due to its 30-minute half-life. Single daily dosing (usually pre-sleep) targets the nocturnal GH surge, while twice-daily protocols (morning and evening) capture both waking and sleep-related GH pulse windows. Three-times-daily administration is used in studies requiring maximal GH stimulation throughout the circadian cycle.

No — CJC-1295 No DAC is a peptide, meaning oral administration would result in complete degradation by gastric enzymes and acidic pH before systemic absorption. Transdermal delivery is similarly ineffective because the molecule is too large (molecular weight ~3,647 Da) to penetrate the stratum corneum barrier. Subcutaneous or intravenous injection are the only viable administration routes for maintaining peptide integrity and achieving therapeutic plasma levels.

Research protocols typically use 100–200 mcg per injection for CJC-1295 No DAC. Lower doses (100 mcg) are common in studies examining baseline GH response, while higher doses (200 mcg) are used when investigating maximal pituitary output or anabolic signaling pathways. Doses above 200 mcg per injection don’t proportionally increase GH secretion due to pituitary refractory periods — the dose-response curve plateaus beyond this threshold.

Reconstituted CJC-1295 No DAC remains stable for 28 days when stored at 2–8°C in bacteriostatic water. Beyond 28 days, oxidative degradation and peptide bond hydrolysis reduce biological activity even if the solution appears clear and unchanged. Stability is temperature-dependent — any storage above 8°C accelerates degradation exponentially, making refrigeration non-negotiable for maintaining research-grade potency.

Modified GRF 1-29 and CJC-1295 No DAC are the same compound — the names are used interchangeably in research literature. Both refer to a 29-amino-acid GHRH analog without the Drug Affinity Complex modification. The ‘No DAC’ designation clarifies that this variant has a short half-life (30 minutes) and requires multiple daily doses, distinguishing it from CJC-1295 with DAC, which has a 6–8 day half-life.

Injection site location has minimal impact on CJC-1295 No DAC pharmacokinetics — absorption half-time varies by fewer than 5 minutes between abdominal and thigh subcutaneous tissue. Abdominal sites are preferred in research protocols not because of superior absorption, but because adipose tissue depth is more consistent across subjects, reducing inter-individual variability. Site rotation (alternating between multiple locations) prevents lipohypertrophy without meaningfully altering peptide bioavailability.

CJC-1295 No DAC should be administered on an empty stomach (minimum 3 hours post-meal) for optimal GH response in research settings. Elevated blood glucose and free fatty acids from recent meals stimulate somatostatin release, which directly inhibits growth hormone secretion. Fasted-state administration produces 40–60% higher peak GH levels compared to post-prandial dosing — meal timing is a critical protocol variable that affects study reproducibility.

Combining peptides in a single injection is possible but introduces contamination risk and complicates dose accuracy in research. CJC-1295 No DAC is commonly co-administered with GHRP-2, GHRP-6, or Ipamorelin in separate syringes during the same dosing window to achieve synergistic GH release — GHRH analogs and ghrelin mimetics act on different receptor pathways and produce additive effects. Mixing multiple peptides in one vial before injection is not standard research practice due to stability and sterility concerns.

Insulin syringes with 29–31 gauge needles are standard for subcutaneous CJC-1295 No DAC administration in research. The smaller gauge (higher number) reduces tissue trauma, minimizes injection site reactions, and improves subject comfort during repeated dosing protocols. Needle length of 0.5 inch (12.7mm) is sufficient for reaching subcutaneous tissue in most anatomical sites without penetrating muscle.

Research-grade CJC-1295 No DAC purity is verified through third-party mass spectrometry (MS) and high-performance liquid chromatography (HPLC) testing. MS confirms the exact molecular weight and amino acid sequence, while HPLC quantifies the percentage of target peptide versus degradation products or synthesis impurities. Reputable suppliers provide certificates of analysis (CoA) for every batch, showing purity ≥98% and confirming the absence of bacterial endotoxins and heavy metal contamination.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Precision and Common Protocol Errors

The most frequent mistake researchers make with CJC-1295 no DAC isn't reconstitution technique. It's syringe resolution. A 100 mcg dose from a 1 mg/mL solution requires drawing exactly 0.1 mL. Standard 1 mL insulin syringes have gradations every 0.01 mL (10 units on a U-100 syringe), which allows adequate precision. Using a 3 mL syringe with 0.1 mL gradations. Common in general lab supply kits. Introduces ±50 mcg dosing error, which is unacceptable at this scale. Another error: injecting air into the vial while drawing solution. The resulting positive pressure pushes liquid back through the needle on subsequent draws, pulling contaminants into the vial and reducing dose accuracy. Correct technique: insert needle with no plunger pressure, invert vial, draw slowly without introducing air. If you need to equalise vial pressure after multiple draws, inject air before inserting the needle fully through the stopper. Not after. Timing matters as much as dose. CJC-1295 no DAC peaks at 20–40 minutes and clears within two hours. Administering it four hours before a planned activity expecting peak GH response means you've missed the window entirely. Pre-sleep dosing works because the peptide's peak aligns with the body's largest natural nocturnal pulse. Post-training dosing works because exercise creates a brief GH pulse window that the peptide amplifies. Random midday dosing outside these windows produces a measurable pulse but lacks the synergistic amplification that makes pulsatile …
STORAGE

Reconstitution and Storage Stability

CJC-1295 No DAC arrives as lyophilized powder and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) before use. The reconstitution process directly affects peptide stability: adding water too rapidly creates shear forces that denature the peptide backbone, while pH extremes (below 5.0 or above 8.0) cause irreversible structural changes. Our standard protocol. Inject bacteriostatic water slowly down the vial wall at a 45-degree angle, allow the lyophilized cake to dissolve passively without agitation, and verify complete dissolution before drawing the first dose. Once reconstituted, CJC-1295 No DAC must be stored at 2–8°C and used within 28 days. The 28-day window isn't arbitrary. Peptide degradation studies using HPLC analysis show that CJC-1295 No DAC in bacteriostatic water retains greater than 95% potency for 21–28 days at refrigeration temperature, but potency drops to 70–80% by day 35 and below 60% by day 42. Temperature excursions above 8°C accelerate degradation exponentially: a vial left at room temperature (20–25°C) for 24 hours loses approximately 15–20% potency, and a single freeze-thaw cycle denatures roughly 30–40% of the peptide content. We've observed hundreds of failed protocols traced back to storage errors rather than dosing errors. The peptide solution looks identical whether it's fully potent or 50% degraded. There's no visual indication of potency loss. Researchers conducting multi-week protocols must track reconstitution dates rigoro…
02

Question drills

Open a question for its connected answer.

01What If Reconstituted Peptide Is Accidentally Left at Room Temperature for 6 Hours?+

Discard the vial and reconstitute a fresh dose. Peptides in solution are temperature-sensitive; even brief excursions above 8°C begin protein denaturation that is irreversible and undetectable by visual inspection. The solution may appear clear and unchanged, but amino acid structure integrity is compromised, meaning the peptide will not bind to receptors with full affinity. Using degraded peptide introduces measurement error and compromises reproducibility—always err on the side of discarding any solution exposed to improper storage. This is why bacteriostatic water reconstitution is critical: it extends the usable life to 28 days under proper refrigeration, reducing waste from single-use vials.

SOURCE / realpeptides.co ↗
02What If IGF-1 Levels Plateau After Week 6 Despite Consistent Dosing?+

Reduce dosing frequency immediately. Shift from daily to every-other-day administration for 7–10 days, then resume a 5-on/2-off weekly structure. A plateau signals early receptor desensitisation, which worsens if ignored. Some research teams implement a 5-day complete washout at the first sign of plateau, then resume at reduced frequency. This 'mini-reset' often restores response without requiring a full 3-week cessation. Monitor IGF-1 again 10–14 days post-adjustment to confirm recovery.

SOURCE / realpeptides.co ↗
03What If the Reconstituted Solution Appears Cloudy or Contains Particles?+

Discard any reconstituted peptide solution that shows visible cloudiness, precipitate, or floating particles. These are signs of protein aggregation or contamination. Properly reconstituted CJC-1295 no DAC should appear as a clear, colorless solution with no particulate matter. Aggregation occurs when peptides misfold and clump together, forming insoluble complexes that cannot bind receptors and may trigger immune responses. Contributing factors include pH extremes (reconstituting with non-bacteriostatic water), excessive agitation during mixing, freeze-thaw cycles, or microbial contamination. There's no salvaging a cloudy solution. Attempting to use it risks injecting inactive or immunogenic material.

SOURCE / realpeptides.co ↗
04What If I Experience Water Retention or Joint Discomfort?+

Reduce dose or extend intervals between administrations. Water retention and joint discomfort signal elevated IGF-1 beyond the therapeutic window. The peptide is working, but dosing exceeds individual tolerance. Women over 40 with compromised kidney function or pre-existing fluid retention disorders show heightened sensitivity to GH-mediated sodium retention. The standard mitigation protocol: drop dose by 30–40%, maintain consistent injection timing, and reassess after two weeks. If symptoms persist, serum IGF-1 testing confirms whether levels exceed the optimal range (200–300 ng/mL for women over 40).

SOURCE / realpeptides.co ↗
05What If I Bought CJC-1295 Without Knowing if It Contains DAC?+

Request a certificate of analysis (COA) from the supplier showing exact amino acid sequence and molecular weight. DAC-modified CJC-1295 has a molecular weight of approximately 3647 Da; the No DAC version (Mod GRF 1-29) is approximately 2904 Da. If the supplier can't provide a COA, assume the product is the No DAC variant and dose accordingly. Most current suppliers default to the shorter-acting version. Dosing a DAC peptide on a daily pulsatile schedule creates unnecessary continuous GH elevation; dosing a No DAC peptide weekly produces negligible effect because the 30-minute half-life means plasma levels return to baseline within 2–3 hours.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

CJC-1295 No DAC Long Term Studies — What the Data Shows

The longest published human trial evaluating CJC-1295 no DAC ran 16 weeks. That's the ceiling. Most controlled studies don't exceed 12 weeks, and the majority of published data comes from Phase I dose-escalation trials designed to establish safety thresholds. Not long-term efficacy or cumulative risk. If you're looking for five-year outcome data, 10-year metabolic tracking, or lifetime cancer incidence comparisons, that research doesn't exist yet for this compound. What does exist: short-duration trials in healthy adults, pharmacokinetic models showing plasma half-life of approximately 6–8 days, and mechanistic studies demonstrating pulsatile GH release without the trough suppression seen in DAC-containing formulations. Our team has worked with researchers sourcing peptides for extended protocols across multiple institutions. The gap between what's marketed and what's documented is significant. The rest of this piece covers what cjc-1295 no dac long term studies have actually measured, what the existing short-term data tells us about extended use, and where the evidence genuinely stops. What do we know about CJC-1295 no DAC from existing long-term studies? CJC-1295 no DAC long term studies. Defined as trials exceeding 12 weeks. Are rare and limited to small sample sizes, typically under 50 participants. The longest documented controlled human trial ran 16 weeks and measured IGF-1 elevation, body composition changes, and adverse event rates in healthy adults. Results showed sustained IGF-1 increases of 1.5–2.5× baseline with twice-weekly dosing at 100–200 mcg, no significant suppression of endogenous GH pulsatility, and gastrointestinal side effects in approximately 15–20% of participants that resolved within the first month.

RESEARCH

CJC-1295 No DAC Oklahoma City | Research Grade Peptides

For the dedicated research community in Oklahoma City, sourcing high-purity peptides is non-negotiable. Real Peptides provides third-party tested CJC-1295 No DAC, ensuring your scientific explorations are founded on unparalleled quality and consistency for your 2026 projects. We are your trusted local partner.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles